Abstract. Nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase 1 (NQO1) protects cells from oxidative damage. NQO1 has been reported to be upregulated in numerous solid tumors, suggesting a role in carcinogenesis and tumor progression. The present study attempted to investigate the clinical prognostic significance of NQO1 overexpression in pancreatic ductal adenocarcinoma (PDAC). A total of 181 tissue specimens were studied, including 126 PDAC and 55 normal pancreas specimens, which were selected for immunohistochemical staining of NQO1 protein.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common types of malignant tumors of the digestive tract, and it has the worst prognosis of all major malignancies, with a 5-year survival rate of 6% and a median survival of 6 months subsequent to diagnosis (1, 2) . Although numerous advances in prevention, surgical resection and adjuvant chemoradiotherapy have led to a decline in the overall mortality due to PDAC, the survival rates for patients with metastatic disease have not significantly improved (3, 4) . Therefore, the identification of an ideal marker for early diagnosis and prognosis evaluation of PDAC has been an important research field in clinical examination.
Nicotinamide adenine dinucleotide phosphate (NADPH): quinone oxidoreducase 1 (NQO1) is located on chromosome 16q22, and consists of six exons and five introns (5) . NQO1 is a flavin adenine dinucleotide-dependent direct two-electron reductase that can use NADH or NADPH as reducing cofactors to reduce quinones to hydroquinones (6) . Several functions of NQO1 have been reported, including xenobiotic detoxification, superoxide scavenging, modulation of p53, maintenance of endogenous antioxidants and proteasomal degradation (7) , suggesting that NQO1 is important in protecting normal cells against oxidative injury and carcinogenesis (8) . NQO1 protein was also observed to be abnormally expressed in numerous human tumors (9, 10) . However, there is limited research investigating the associations between NQO1 expression and PDAC development and progression.
Thus, the current study aimed to demonstrate the association between NQO1 expression and clinicopathological characteristics of patients with PDAC. The present results revealed that NQO1 was significantly upregulated in PDAC, which was associated with tumor grade, tumor node-metastasis (TNM) stage, lymph node (LN) metastasis and overall survival (OS) of patients with PDAC. NQO1 may be an independent prognostic biomarker for patients with PDAC.
Materials and methods
Ethics statement. The present study complied with the principles of the Declaration of Helsinki, and was approved by the human ethics and research ethics committees of Yanbian Immunohistochemical (IHC) analysis. IHC analysis was performed using the LSAB kit (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA). Prior to IHC staining, all sections were deparaffinized, rehydrated and incubated with 3% H 2 O 2 in methanol for 15 min at RT. The antigen was retrieved at 95˚C for 20 min by placing the slides in 0.01 M sodium citrate buffer (pH 6.0). The slides were then incubated with the aforementioned anti-NQO1 monoclonal antibody (dilution, 1:200) at 4˚C overnight. Subsequent to incubation with a biotinylated secondary antibody (pre-diluted; cat. no. PV9000; OriGene Technologies, Inc., Beijing, China) at RT for 30 min, the slides were incubated with a streptavidin-peroxidase complex (cat. no. PV9000; OriGene Technologies, Inc.) at RT for 30 min. IHC staining was developed using 3,3'-diaminobenzidine, and Mayer's hematoxylin (cat. no., ZLI9610; OriGene Technologies, Inc.) was used for counterstaining. Mouse immunoglobulin G (pre-diluted; cat. no. PV9000; OriGene Technologies, Inc.) was used as an isotype control, incubation at RT for 30 min. A negative control was utilized by processing the tissue sections without the primary antibody.
Evaluation of IHC staining. All tissue specimens were blindly examined by two pathologists. In case of discrepancies, a final score was established by reassessment on a double-headed microscope. Immunostaining for NQO1 was semi-quantitatively scored as: -, <5% positive cells; +, 5-25% positive cells; ++, 26-50% positive cells; and +++, >50% positive cells. Cytoplasmic or nuclear NQO1 staining was considered to be positive staining. Tissue sections scored as ++, and +++ were considered to be strong positive staining. For survival data analysis, ++ or +++ scored samples were considered high-level NQO1 expression, while -or + scored samples were considered to exhibit low levels of NQO1 expression.
Statistical analysis. All statistical analyses were performed using SPSS (version 17.0; SPSS, Inc., Chicago, IL, USA) software. χ 2 test and Fisher's exact test, were used to assess the association between clinicopathological characteristics and the expression of studied protein. The survival rates following tumor removal were calculated using the Kaplan-Meier estimator and differences in survival curves were analyzed using log-rank tests. Multivariate survival analysis was performed on all the significant characteristics measured by univariate survival analysis through the Cox proportional hazards regression model. P<0.05 was considered to indicate a statistically significant difference.
Results

High expression of NQO1 protein in PDACs.
The positive rate of NQO1 protein expression in PDAC tissue was significantly increased compared with that in normal pancreatic tissues (83.3%, 105/126, P<0.01). Similarly, the strongly positive rate of NQO1 expression in PDAC tissue was increased compared with that in normal pancreatic tissues (65.9%, 83/126, P<0.01; Table I ). IF staining revealed that NQO1 protein was mainly located in the cytoplasm and nucleus of BxPC-3 cells (Fig. 1) . Consistently, IHC staining demonstrated that NQO1 protein localized to the cytoplasm of PDAC tissues (Fig. 2) .
Clinicopathological significance of NQO1 expression in patients with PDAC. The present study investigated the association between NQO1 expression and the clinicopathological features of patients with PDAC. According to the clinical parameters listed in Fig. 3) .
To additionally confirm the importance of NQO1 in PDAC, the present study analyzed the OS of 162 patients with PDAC using the Kaplan-Meier method. Patients with high NQO1 expression exhibited a lower rate of OS compared with those with low NQO1 expression (log-rank=22.755, P<0.001; Fig. 4A ). Similarly, survival of patients with G1 (log-rank=7.317, P<0.01), G2 (log-rank=8.025, P<0.01) and G3 (log-rank=9.037, P= 0.003) was significantly lower in PDAC tissues exhibiting high NQO1 expression compared with those that in tissues exhibiting low NQO1 expression (Fig. 4B-D) . Patients with PDAC and NQO1 positive expression had lower OS rates compared with those without NQO1 expression in the absence (log-rank=19.291, P<0.001) and presence of LN metastasis (log-rank=5.259, P=0.022) (Fig. 5) . Furthermore, patients with PDAC exhibiting high NQO1 expression displayed decreased OS compared with those with low NQO1 expression in early stage patients (log-rank=18.402, P<0.001; Fig. 6 ). (14) as a cytosolic flavoenzyme that reduces quinones to less toxic hydroquinones in a single two-electron transfer step (15) . Subsequent to decades of research, it is currently known that Table I . Nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 protein expression in pancreatic ductal adenocarcinoma. NQO1 can induce a series of defensive factors to prevent the damage caused by exogenous substances, oxidants, and ultraviolet and ionizing radiation (16) . NQO1 is additionally involved in the maintenance of the active forms of coenzyme Q and vitamin E, the regulation of the immune response and autoimmunity and the stabilization of the tumor suppressors p53, p73a and p33 (17) . As a cell protector, there is evidence that NQO1 expression was significantly increased in the cytoplasm and nucleus of certain human solid tumors (18) . Malkinson et al (19) observed that NQO1 was highly expressed in human lung cancer tissues. Cheng et al (20) demonstrated that NQO1 expression was significantly increased in primary melanomas compared with that in dysplastic nevi, and that this may occur in the initiation stage of melanoma development. Our previous studies have shown that the expression of NQO1 protein was significantly high in non-small cell lung cancer (21) , serous ovarian carcinoma (22) and gastric adenocarcinoma (23) , indicating that the expression of NQO1 was associated with the occurrence of tumors, and that it may be a significant prognostic or predictive marker. However, the role of NQO1 as a biomarker in PDAC is unclear.
NQO1 expression is an independent prognostic biomarker in
Discussion
NQO1 was identified by Ernster and Navazio in 1958
Positive patients -----------------------------------------------------------------
In the present study, IHC staining of NQO1 protein in PDAC tissue was performed, and it was observed that staining of NQO1 is localized in the cytoplasm. IF staining also revealed that NQO1 protein localized in the cytoplasm and nucleus of BxPC-3 cells. In these tissues, the strongly positive rate of NQO1 protein was 65.9% (83/126) in PDAC tissue, which was significantly greater than that in normal pancreas tissue, indicating that NQO1 may serve an important role in the progression of PDAC. The current study analyzed the association between high expression of NQO1 protein and the clinicopathological parameters of PDAC; the results indicated that the rate of strongly positive NQO1 protein expression in G2 and G3 PDAC was increased compared with that in G1 PDAC. Additionally, high NQO1 expression was significantly associated with LN metastasis and TNM stage, which is consistent with the study by Mikami et al (24) , suggesting that NQO1 upregulation promotes the invasion and metastasis of PDAC.
Buranrat et al (25) reported a significant association between high level of NQO1 expression and short OS time of patients with cholangiocarcinoma, which raised the possibility of using NQO1 as a tumor marker. In the present study, univariate survival analysis revealed that tumor size (P=0.045), TNM stage (P<0.001), LN metastasis (P=0.035) and NQO1 expression (P<0.001) status were all significantly associated with OS of patients with serous PDAC. Additionally, multivariate survival analysis revealed that NQO1 expression was a prognostic factor of PDAC, along with TNM stage. Overall, the present results indicate that NQO1 may be a biomarker for early diagnosis and prognosis, and a potential molecular target in patients with PDAC.
Recent studies have reported that anti-tumor agents such as β-lapachone and deoxynyboquinone (DNQ) effectively kill cancer cells through NQO1 specific activation (26, 27) . Huang et al reported that the potency and NQO1-dependent therapeutic window of DNQ and its apparent reduced metabolism by one-electron oxidoreductases make DNQ or its derivatives a promising avenue for study (28) .
In conclusion, NQO1 is important in the occurrence of PDAC, and may serve as an important marker and potential therapeutic target for PDAC. Therefore, additional research may verify whether NQO1 inhibitors could be used in the treatment of patients with PDAC. 
